These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22410611)

  • 1. Interaction of human cytochrome P4503A4 with ritonavir analogs.
    Sevrioukova IF; Poulos TL
    Arch Biochem Biophys; 2012 Apr; 520(2):108-16. PubMed ID: 22410611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir.
    Sevrioukova IF; Poulos TL
    Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18422-7. PubMed ID: 20937904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.
    Sevrioukova IF; Poulos TL
    J Med Chem; 2013 May; 56(9):3733-41. PubMed ID: 23586711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting cytochrome P450 3A4-ligand interactions using ritonavir analogues.
    Sevrioukova IF; Poulos TL
    Biochemistry; 2013 Jul; 52(26):4474-81. PubMed ID: 23746300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism.
    Sevrioukova IF; Poulos TL
    Curr Top Med Chem; 2014; 14(11):1348-55. PubMed ID: 24805065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of CYP3A4 with the inhibitor cobicistat: Structural and mechanistic insights and comparison with ritonavir.
    Sevrioukova IF
    Arch Biochem Biophys; 2024 Aug; 758():110071. PubMed ID: 38909836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Human CYP3A4 by Rationally Designed Ritonavir-Like Compounds: Impact and Interplay of the Side Group Functionalities.
    Samuels ER; Sevrioukova I
    Mol Pharm; 2018 Jan; 15(1):279-288. PubMed ID: 29232137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
    Jayakanthan M; Chandrasekar S; Muthukumaran J; Mathur PP
    J Mol Graph Model; 2010 Jan; 28(5):455-63. PubMed ID: 19931478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Activity Relationships of Rationally Designed Ritonavir Analogues: Impact of Side-Group Stereochemistry, Headgroup Spacing, and Backbone Composition on the Interaction with CYP3A4.
    Samuels ER; Sevrioukova I
    Biochemistry; 2019 Apr; 58(15):2077-2087. PubMed ID: 30912932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of CYP3A4 with Rationally Designed Ritonavir Analogues: Impact of Steric Constraints Imposed on the Heme-Ligating Group and the End-Pyridine Attachment.
    Samuels ER; Sevrioukova IF
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength.
    Samuels ER; Sevrioukova IF
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of Human Drug-Metabolizing CYP3A4 with Small Inhibitory Molecules.
    Sevrioukova I
    Biochemistry; 2019 Feb; 58(7):930-939. PubMed ID: 30676743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4.
    Nookala AR; Li J; Ande A; Wang L; Vaidya NK; Li W; Kumar S; Kumar A
    PLoS One; 2016; 11(1):e0146529. PubMed ID: 26741368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4.
    Rock BM; Hengel SM; Rock DA; Wienkers LC; Kunze KL
    Mol Pharmacol; 2014 Dec; 86(6):665-74. PubMed ID: 25274602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.
    Kaur P; Chamberlin AR; Poulos TL; Sevrioukova IF
    J Med Chem; 2016 May; 59(9):4210-20. PubMed ID: 26371436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4.
    Samuels ER; Sevrioukova IF
    Bioorg Med Chem; 2020 Mar; 28(6):115349. PubMed ID: 32044230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.
    Koudriakova T; Iatsimirskaia E; Utkin I; Gangl E; Vouros P; Storozhuk E; Orza D; Marinina J; Gerber N
    Drug Metab Dispos; 1998 Jun; 26(6):552-61. PubMed ID: 9616191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.
    Flentge CA; Randolph JT; Huang PP; Klein LL; Marsh KC; Harlan JE; Kempf DJ
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5444-8. PubMed ID: 19679477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
    Loos NHC; Beijnen JH; Schinkel AH
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Level Production and Properties of the Cysteine-Depleted Cytochrome P450 3A4.
    Sevrioukova IF
    Biochemistry; 2017 Jun; 56(24):3058-3067. PubMed ID: 28590129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.